

TABLE 81: INCLUDED STUDY CHARACTERISTICS — COMBINED TREATMENT EXPERIENCE (N = 24 + 2)

| AUTHOR, YEAR, STUDY NAME (IF AVAILABLE) | TOTAL N | PREVIOUS TREATMENT EXPERIENCE | POPULATION | TREATMENTS | COUNTRIES | RANDOM- IZED (Y/N) | NAIVE GENOTYPE | | | | | | EXPERIENCED GENOTYPE | | | | |
|--|---------|-------------------------------------|--|--|--------------------------------|-----------------------|-------------------|---|---|---|---|---|-------------------------|---|---|---|--|
| | | | | | | | 1 | 2 | 3 | 4 | 5 | 6 | 1 | 2 | 3 | 4 | |
| Included in the NMA for all SVR | | | | | | | | | | | | | | | | | |
| Dieterich et al., 2014 | 106 | Combined | 18 to 70 years Genotype 1 HIV coinfection | SIM12 PR24-48 RGT SIM12 PR48 SIM12 PR48 | Europe, N. America | No | Y | | | | | | | Y | | | |
| Gane et al., 2013 ELECTRON | 95 | Combined | > 18 years Genotype 2 or 3 No cirrhosis | SOF12 + RBV12 SOF12 + PR12 | New Zealand | Yes | Y | Y | | | | | | Y | | | |
| Gane et al., 2014 ELECTRON | 96 | Combined | > 18 years Genotype 2 or 3 No cirrhosis | SOF12 + LDV12 + RBV12 | New Zealand | Yes | Y | | | | | | | Y | | | |
| Jacobson et al., 2013 Fusion | 202 | Experienced | ≥ 18 years Genotype 2 or 3 With or without cirrhosis | SOF12 + RBV12 | USA, Canada, New Zealand | Yes | | | | | | | | | Y | | |
| Kumada et al., 2014 | 259 | Combined | 20 to 75 years Genotype 1b ≤ 10% of patients could have compensated cirrhosis | DCV24 + ASU24 | Japan | No | Y | | | | | | | Y | | | |

| AUTHOR, YEAR, STUDY NAME (IF AVAILABLE) | TOTAL N | PREVIOUS TREATMENT EXPERIENCE | POPULATION | TREATMENTS | COUNTRIES | RANDOMIZED (Y/N) | NAIVE GENOTYPE | | | | | | EXPERIENCED GENOTYPE | | | | | |
|---|---------|-------------------------------|--|---|-------------------------------------|------------------|----------------|---|---|---|---|---|----------------------|---|---|---|--|--|
| | | | | | | | 1 | 2 | 3 | 4 | 5 | 6 | 1 | 2 | 3 | 4 | | |
| Lalezari et al., 2015 | 38 | Combined | 18 to 70 years Genotype 1 No cirrhosis | PAR/RIT12 + OMB12 + DAS12 + RBV12 | United States | No | Y | | | | | | | | | | | |
| Lawitz et al., 2014 COSMOS | 168 | Combined | 18 to 70 years Genotype 1 METAVIR F3 or 4 fibrosis | SOF12+ SIM12 + RBV12 SIM12 + SOF12 | USA, Puerto Rico | Yes | Y | | | | | | Y | | | | | |
| Lawitz et al., 2014 LONESTAR | 100 | Combined | ≥ 18 years Genotype 1 Cirrhosis | SOF8 + LDV8 SOF8 + LDV8 + RBV8 SOF12 + LDV12 SOF12 + LDV12 + RBV12 | USA | Yes | Y | | | | | | Y | | | | | |
| Manns et al., 2014 HALLMARK-DUAL | 205 | Naive | ≥ 18 years | DCV24 + ASU24 | N. and S. America, Europe, and Asia | Yes No | Y | | | | | | Y | | | | | |
| | 440 | Combined | Genotype 1b ≤ 25% of patients could have compensated cirrhosis | | | | | | | | | | | | | | | |
| Mizokami et al., 2015 | 341 | Combined | ≥ 20 years Genotype 1 ≤ 40% of patients could have compensated cirrhosis | SOF12 + LDV12 SOF12 + LDV12 + RBV12 | Japan | Yes | Y | | | | | | Y | | | | | |

| AUTHOR, YEAR, STUDY NAME (IF AVAILABLE) | TOTAL N | PREVIOUS TREATMENT EXPERIENCE | POPULATION | TREATMENTS | COUNTRIES | RANDOMIZED (Y/N) | NAIVE GENOTYPE | | | | | | EXPERIENCED GENOTYPE | | | | | |
|---|--|-------------------------------|--|--|--------------------------------|------------------|----------------|---|---|---|---|---|----------------------|---|---|---|---|--|
| | | | | | | | 1 | 2 | 3 | 4 | 5 | 6 | 1 | 2 | 3 | 4 | | |
| Molina et al., 2015 PHOTON-2 | 275 | Combined | ≥ 18 years Genotype 1, 2, 3 or 4 for naive patients; genotype 2 or 3 for experienced patients HIV-1 coinfection | SOF24 + RBV24 SOF12 + RBV12 | Australia, Europe | No | Y | Y | Y | Y | | | | | N | Y | | |
| Muir et al., 2015 UNITY-2 | 202 | Combined | ≥ 18 years Genotype 1 Compensated cirrhosis | DCV12 + ASU12 + BEC12 + RBV12 DCV12 + ASU12 + BEC12 | USA, Canada, France, Australia | Yes | Y | | | | | | N | | | | | |
| Nelson D. et al., Accepted in 2015 ALLY-3 (AI444-218) | 152 (Treatment-naive = 101; treatment-exp = 51) | Combined | ≥ 18 years Genotype 3 Compensated cirrhosis eligible | DCV12 + SOF12 | USA, Puerto Rico | No | | | Y | | | | | | | | Y | |
| Omata M et al., 2014 | 153 (Treatment-naive = 90; treatment exp = 63) | Combined | ≥ 20 years Genotype 2 | SOF12 + RBV12 | Japan | No | | Y | | | | | | Y | | | | |
| Pearlman et al., 2015 | 93 | Combined | ≥ 18 years Genotype 1a Cirrhosis | SIM12 + SOF12 SOF12 + PR12 | USA | Yes | Y | | | | | | Y | | | | | |

| AUTHOR, YEAR, STUDY NAME (IF AVAILABLE) | TOTAL N | PREVIOUS TREATMENT EXPERIENCE | POPULATION | TREATMENTS | COUNTRIES | RANDOMIZED (Y/N) | NAIVE GENOTYPE | | | | | | EXPERIENCED GENOTYPE | | | | | |
|---|---------|-------------------------------|---|--------------------------------|--------------------------------|------------------|----------------|---|---|---|---|---|----------------------|---|---|---|---|---|
| | | | | | | | 1 | 2 | 3 | 4 | 5 | 6 | 1 | 2 | 3 | 4 | | |
| Poordad et al. et al., 2015 UNITY-1 | 415 | Combined | ≥ 18 years Genotype 1 No cirrhosis | DCV12 + ASU12 + BEC12 | USA, Canada, France, Australia | No | Y | | | | | | | N | | | | |
| Ruane et al., 2014 | 60 | Combined | ≥ 18 years Genotype 4 ≤ 20% of patients may have compensated cirrhosis | SOF12 + RBV12 SOF24 + RBV24 | USA | Yes | | | | Y | | | | | | | | Y |
| Sulkowski et al., 2014 | 224 | Combined | ≥ 18 years Genotype 1, 2, or 3 for naive patients; genotype 2 or 3 for experienced patients < 20% of patients were permitted to have cirrhosis HIV coinfection | SOF12 + RBV12 SOF24 + RBV24 | USA and Puerto Rico | No | Y | Y | | | | | | | | | Y | |
| Sulkowski et al., 2014 | 211 | Combined | 18 to 70 years Genotype 1, 2, or 3 No evidence of cirrhosis | DCV12 + SOF12 | USA | Yes | Y | | | | | | | | | | | |
| Zeuzem et al., 2014 | 334 | Combined | ≥ 18 years Genotype 2 or 3 | SOF12 + RBV12 SOF24 + RBV24 | Europe | No | | | Y | | | | | Y | Y | | | |

| AUTHOR, YEAR, STUDY NAME (IF AVAILABLE) | TOTAL N | PREVIOUS TREATMENT EXPERIENCE | POPULATION | TREATMENTS | COUNTRIES | RANDOMIZED (Y/N) | NAIVE GENOTYPE | | | | | | EXPERIENCED GENOTYPE | | | | |
|---|---------|-------------------------------|---|--|-------------------------------------|------------------|----------------|---|---|---|---|---|----------------------|---|---|---|--|
| | | | | | | | 1 | 2 | 3 | 4 | 5 | 6 | 1 | 2 | 3 | 4 | |
| | | | Approximately 20% of patients could have cirrhosis | | | | | | | | | | | | | | |
| Not included in the NMA for all SVR | | | | | | | | | | | | | | | | | |
| Jacobson et al., 2013 POSITRON | 280 | Combined | ≥ 18 years Genotype 2 or 3 With or without cirrhosis | SOF12 + RBV12 | USA, Canada, Australia, New Zealand | Yes | | | | | | | | | | | |
| Lawitz et al., 2015 C-WORTHY; Sulkowski et al., 2015 C-WORTHY | 471 | Combined | ≥ 18 years Genotype 1 Part A: no cirrhosis Part B and C: with or without cirrhosis, or HIV coinfection without cirrhosis | GRZ12 + ELB12 (50 mg q.d.) GRZ18 + ELB18 (50 mg q.d.) GRZ12 + ELB12 (50 mg q.d.) + RBV12 GRZ18 + ELB18 (50 mg q.d.) + RBV18 GRZ12 + ELB12 + RBV12 GRZ8 + ELB8 (50 mg q.d.) + RBV8 | USA, Asia, Europe, Canada | Yes | N | | | | | | | N | | | |

| AUTHOR, YEAR, STUDY NAME (IF AVAILABLE) | TOTAL N | PREVIOUS TREATMENT EXPERIENCE | POPULATION | TREATMENTS | COUNTRIES | RANDOM-IZED (Y/N) | NAIVE GENOTYPE | | | | | | EXPERIENCED GENOTYPE | | | | | |
|--|---------|-------------------------------|---|--|-------------------------|-------------------|----------------|---|---|---|---|---|----------------------|---|---|---|--|--|
| | | | | | | | 1 | 2 | 3 | 4 | 5 | 6 | 1 | 2 | 3 | 4 | | |
| Poordad et al., 2014 TURQUOISE-II | 381 | Combined | 18 to 70 years Genotype 1 Compensated cirrhosis | PAR/RIT12 + OMB12 + DAS12 + RBV12 PAR/RIT24 + OMB24 + DAS24 + RBV24 | Canada, USA, and Europe | Yes | | | | | | | | | | | | |
| Sulkowski et al., 2015 TURQUOISE-I-1a | 63 | Combined | 18 to 70 years Genotype 1 HIV-1 coinfection | PAR/RIT12 + OMB12 + DAS12 + RBV12 | USA, Puerto Rico | Yes | | | | | | | | | | | | |

ASU = asunaprevir; BEC = beclabuvir; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; NMA = network meta-analysis; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q.d. = once daily; RBV = ribavirin; RGT = response-guided therapy; RIT = ritonavir; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response.

NOTE: PLEASE REFER TO TREATMENT REGIMEN NOMENCLATURE TABLE FOR DESCRIPTION OF DOSAGES.